Stay up-to-date with the Divis Labs Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on ...

Stay up-to-date with the Divis Labs Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...

The brokerage said Divis Laboratories is entering a stronger growth phase, supported by a robust H2FY26 pipeline and visibility for scale-up over the next two years.

Stock market today: Indian equity indices remained largely unchanged on Wednesday as financial stocks retraced from their near-record peaks, counterbalancing the positive sentiment surrounding a ...

Earnings call Divi's Laboratories posted a 25.4% YoY revenue growth for Q3 FY25, with PAT rising 64.5% YoY. Custom synthesis continues to drive growth, while backward integration via the new Kakinada ...

Revenue stood at INR 25,850 Mn., up 12.2% YoY, below our estimates by 9.1%, led by weaker growth in Custom Synthesis segment. EBITDA came in at INR 8,860 Mn., up by 21.2% YoY (+19.2% QoQ), largely ...

Shares of Divis Laboratories rose 3 percent to Rs 6,188 on Friday, August 22, after global brokerage Citi turned upbeat on the stock, flagging attractive valuations and sector tailwinds. Citi ...

Divi's Laboratories proposes ₹30 per share final dividend for FY25 Stock price reaches record ₹6,764, up 4.37 percent New long-term pharma supply deal triggers ₹650-750 crore investment Shares of ...

Benchmark indices closed lower on Monday tracking weak global markets amid concerns over US President Donald Trump imposing tariffs on some of its trading partners. Stocks that were in focus include ...

Indian benchmark indices posted mild gains on Tuesday after trading in a tight range following a sharp rally last week. After geopolitical concerns, traders have shifted their attention towards the ...

> Icon, an Ireland-based clinical research company, said it will open a new global innovation hub in the country that will create 200 new jobs. Announcement > Indian API maker Divis Laboratories ...

Earnings call Divi’s Laboratories reported Q2 FY25 consolidated revenue of ₹2,444 crore, up 22.5% YoY and 11.2% QoQ. Profit after tax rose to ₹510 crore, up 46.6% YoY. Custom synthesis now contributes ...